26-02-2026, 22:00

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Notified -
Globe Newswire26-02-2026, 22:00
13-11-2024, 22:57

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
Globe Newswire13-11-2024, 22:57
1-10-2024, 18:45

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
Globe Newswire1-10-2024, 18:45
16-11-2023, 17:14

Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
Globe Newswire16-11-2023, 17:14